Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristof Cuppens

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Cancers|June 22, 2023
Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical ApplicationsOlivia Vandekerckhove, Kristof Cuppens, Karin Pat, et al.
Case Reports in Oncology|October 30, 2023
Sjögren's Syndrome Caused by PD-1 Inhibition in a Lung Cancer PatientAaron Caeyman, Olivia Vandekerckhove, Karin Pat, et al.
Lung Cancer (Amsterdam, Netherlands)|June 11, 2022
HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitorsKristof Cuppens, Paul Baas, Ellen Geerdens, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 16, 2014
A rare central thoracic tumorKristof Cuppens, Marion Delcroix, Dirk Van Raemdonck, et al.
Drugs - Real World Outcomes|March 12, 2021
Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL StudyKristof Cuppens, Liesbet Lodewyckx, Ingel Demedts, et al.
Critical Reviews in Oncology/Hematology|December 3, 2021
Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinibAhmad Awada, Thierry Berghmans, Paul M Clement, et al.
Journal of Clinical Medicine|March 25, 2022
Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and TreatmentAbed Agbarya, Walid Shalata, Alfredo Addeo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 13, 2025
Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung)Kristof Cuppens, Marcel Wiesweg, Paul Baas, et al.
Nature Medicine|April 30, 2024
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trialMartin Schuler, Kristof Cuppens, Till Plönes, et al.
Acta Oncologica (Stockholm, Sweden)|May 16, 2022
A prospective, multicenter, noninterventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancerAnne Sibille, Frederique Bustin, Luciano Carestia, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Cancers|June 22, 2023
Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical ApplicationsOlivia Vandekerckhove, Kristof Cuppens, Karin Pat, et al.
Case Reports in Oncology|October 30, 2023
Sjögren's Syndrome Caused by PD-1 Inhibition in a Lung Cancer PatientAaron Caeyman, Olivia Vandekerckhove, Karin Pat, et al.
Lung Cancer (Amsterdam, Netherlands)|June 11, 2022
HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitorsKristof Cuppens, Paul Baas, Ellen Geerdens, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 16, 2014
A rare central thoracic tumorKristof Cuppens, Marion Delcroix, Dirk Van Raemdonck, et al.
Drugs - Real World Outcomes|March 12, 2021
Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL StudyKristof Cuppens, Liesbet Lodewyckx, Ingel Demedts, et al.
Critical Reviews in Oncology/Hematology|December 3, 2021
Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinibAhmad Awada, Thierry Berghmans, Paul M Clement, et al.
Journal of Clinical Medicine|March 25, 2022
Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and TreatmentAbed Agbarya, Walid Shalata, Alfredo Addeo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 13, 2025
Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung)Kristof Cuppens, Marcel Wiesweg, Paul Baas, et al.
Nature Medicine|April 30, 2024
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trialMartin Schuler, Kristof Cuppens, Till Plönes, et al.
Acta Oncologica (Stockholm, Sweden)|May 16, 2022
A prospective, multicenter, noninterventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancerAnne Sibille, Frederique Bustin, Luciano Carestia, et al.
Pageof 3